Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cel-Sci Corp (AMEX:CVM) (was HIV) -- Ignore unavailable to you. Want to Upgrade?

To: Jerry A. Balcolm who wrote (2722)	9/30/1999 6:13:00 AM
From: MMender	Read Replies (1) \| Respond to of 2836

What happens if new co sold.,Money doesn't float around, From my hospital bed I don't see it coming to cel sci. I see it going to zmaxPhsrms, zmaybe because I am somtime out of it. please poimt me down the right trail. simple English please no suppositions, Thsnks MMender

To: Jerry A. Balcolm who wrote (2722)	10/7/1999 6:01:00 PM
From: Tom Shutters	Read Replies (2) \| Respond to of 2836

"New Acceptance of Chemoradiation Will Help Boost Head and Neck Cancer Therapy Market, Reports Decision Resources, In." ..."Clinicians believe that this synergy between chemotherapy and radiation represents the first significant advance in the treatment of advanced disease in two decades"... news.excite.com "Decision Resources Report Projects Robust Annual Growth in the Sale of Cytokine-Based Therapies Through 2008." dresources.com

To: Jerry A. Balcolm who wrote (2722)	11/3/1999 6:27:00 PM
From: Tom Shutters	Read Replies (3) \| Respond to of 2836

"Virus-cell interaction provides new HIV vaccine target" ..."Much research is currently focused on the mechanism of HIV entry into cells and could lead to the development not only of antiretroviral drugs but also vaccines, Dr. Anthony S. Fauci commented at the 12th Colloque des Cent Gardes held here this week"... ..."And that part, which is just very briefly exposed during the conformational change of the gp120 and gp41, is now the subject of targets for small peptides to bind it." Most of the presentations concerning viral entry address this concept either directly or indirectly." "This is an area of "considerable hot interest" now, Dr. Fauci pointed out. Research efforts are concentrated around designing peptides that interfere with the binding of the epitopes that are hidden until the point of fusion." "There's no doubt that the peptides will work in inhibiting binding," he continued. The critical question is "...can you get it in the form that can be administered so the concentration of the peptide would be appropriate and pharmacologically relevant enough to do the blocking." "The problem with peptides is that they are large molecules that have difficulty getting into the mucosa of the gut. Right now, these molecules are administered by injection. Once researchers get them into a "...soluble form that is orally available...I think you're going to have something that is really hot."... ..."We may be able to "...exploit what looks like an Achilles' heel of the molecule," Dr. Ruprecht said. It also looks like "...the problem of clades may not be as difficult to overcome as we previously thought." ama-assn.org